| Characteristic | Growth per year |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
April 2019
More information
Region
Worldwide
Survey time period
as of April 2019
Supplementary notes
Products that have orphan and non-orphan drug
designations and are expected to generate less than 50% of their sales in 2018 and 2024 from
their orphan-designated indication/s, are excluded from this analysis. This has led to the exclusion
of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
* From 2019 on projected.
Citation formats
